Connect Biopharma Holdings Ltd - ADR Stock

$0.85

8.12% yesterday

Nasdaq, May 20, 10:17 pm CET

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Connect Biopharma Holdings Ltd - ADR Stock price

$0.85

-16.15 95.01% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.06 8.12%

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$46.97m
Enterprise Value	$-46.56m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.92
EV/Sales (TTM) EV/Sales	-1.79
P/S ratio (TTM) P/S ratio	1.80
P/B ratio (TTM) P/B ratio	0.57
Revenue (TTM) Revenue	$26.03m
EBIT (operating result TTM) EBIT	$-22.39m
Free Cash Flow (TTM) Free Cash Flow	$-24.30m
Cash position	$84.00m
EPS (TTM) EPS	$-0.28
P/E forward	negative
Short interest	0.14%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Connect Biopharma Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Connect Biopharma Holdings Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	26 26	- 100%
- Direct Costs	0.66 0.66	- 3%
Gross Profit	25 25	- 97%
- Selling and Administrative Expenses	18 18	- 69%
- Research and Development Expense	29 29	- 112%
EBITDA	-22 -22	- -83%
- Depreciation and Amortization	0.66 0.66	- 3%
EBIT (Operating Income) EBIT	-22 -22	- -86%
Net Profit	-16 -16	- -60%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Connect Biopharma Holdings Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

about 15 hours ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated st ructural and molecul...

Neutral

GlobeNewsWire

●

6 days ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 study supporting potential of rademikibart as a novel biologic treatment for patients with asthma and Type 2 inflammation Strong balance she...

Neutral

GlobeNewsWire

●

7 days ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the initiati...

More Connect Biopharma Holdings Ltd - ADR News

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Head office	Cayman Islands
CEO	Barry Quart
Employees	62
Founded	2015
Website	www.connectbiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now